Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival
Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response
FDA Grants Accelerated Approval to Imbruvica
Two Papers Evaluate CyberKnife Survival Rates and Tolerability
ANG1005 Demonstrates Activity In Patients with Brain Metastases
MM-121 Study Fails PFS Endpoint, Biomarker Analysis Continues
AGS-003 Immunotherapy Induces T Cell Responses in Phase II Trial
NCI CTEP Approved Trials For the Month of November
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - In the epicenter of the measles outbreak, “love thy neighbor” does not extend to vaccination rates
A dispatch from Lancaster County - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Anthony El-Khoueiry named director of USC Norris
- Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on - As Iowa goes blue, incoming Gov. Rob Sand and Sen. Josh Turek offer plans to address the state’s “cancer crisis”









